Penn Medicine Scientists Pioneer Breakthrough in Preventing Breast Cancer Recurrence by Targeting Dormant Cancer Cells

A groundbreaking, federally funded clinical trial has unveiled a revolutionary strategy to identify breast cancer survivors at elevated risk of recurrence due to dormant cancer cells and to effectively eliminate these insidious cells using existing, repurposed medications. This first-of-its-kind research, spearheaded by scientists from the Abramson Cancer Center at the University of Pennsylvania and Penn’s Perelman School of Medicine, marks a significant leap forward in oncology and was formally published today in the prestigious journal Nature Medicine. The findings present a tangible hope for millions of survivors who live under the persistent threat of their cancer returning, offering a proactive intervention where previously only a "wait and see" approach existed.

The Persistent Challenge of Breast Cancer Relapse

Despite remarkable advancements in early detection and treatment modalities over recent decades, breast cancer recurrence remains a formidable and often incurable challenge. While overall survival rates continue to climb, an estimated 30 percent of women and men who initially overcome breast cancer will experience a relapse. Once breast cancer returns after initial treatment, particularly in its metastatic form, it is generally considered incurable, necessitating continuous, indefinite treatment regimens that manage but rarely fully eradicate the disease. The timing of recurrence can vary dramatically depending on the cancer subtype: aggressive forms like triple-negative breast cancer (TNBC) and HER2-positive breast cancer often recur within a few years of initial treatment, while hormone receptor-positive (ER+) breast cancers can unpredictably resurface decades later, leaving survivors in a perpetual state of anxiety. Until now, oncologists lacked a reliable method to identify these high-risk individuals in real time or to intervene with preventative therapies capable of targeting the elusive dormant cells responsible for future relapse.

A Novel Approach: Targeting Minimal Residual Disease

The Penn Medicine study focused on what are known as "dormant tumor cells" or "minimal residual disease" (MRD). These are cancer cells that survive initial treatments but do not actively proliferate. Instead, they lie quiescent, often scattered throughout the body, particularly in sites like the bone marrow, for extended periods – sometimes years or even decades. Because these cells are not actively growing or dividing, they do not appear on standard imaging tests such as mammograms, CT scans, or PET scans, which are designed to detect metabolically active or structurally evident tumors. This invisibility renders them undetectable by conventional surveillance methods, making the task of preventing recurrence exceedingly difficult. However, once these "sleeper cells" are reactivated, they can begin to expand, circulate in the bloodstream, and seed new tumors, leading to the devastating spread of metastatic breast cancer. Patients identified with MRD are known to face a significantly higher likelihood of experiencing breast cancer recurrence and have decreased overall survival.

Breakthrough Clinical Trial Results

The Phase II CLEVER clinical trial, a randomized study involving 51 breast cancer survivors, demonstrated the remarkable efficacy of repurposed, existing drugs in clearing these dormant tumor cells. The trial’s results were compelling: a staggering 80 percent of participants who received treatment successfully cleared their dormant tumor cells. More importantly, the long-term outcomes were exceptionally promising. After a median follow-up period of 42 months (3.5 years), the three-year survival rate without any disease recurrence was above 90 percent in patients who received monotherapy with one of the study drugs. For patients who received combination therapy with both study drugs, the disease-free survival rate reached an unprecedented 100 percent. These figures represent a significant improvement over historical recurrence rates for high-risk patients and offer a profound shift in the potential for post-treatment management.

Dr. Angela DeMichele, MD, MSCE, FASCO, the principal investigator and Mariann T. and Robert J. MacDonald Professor in Breast Cancer Research, articulated the deep impact of these findings: "The lingering fear of cancer returning is something that hangs over many breast cancer survivors after they celebrate the end of treatment. Right now, we just don’t know when or if someone’s cancer will come back – that’s the problem we set out to solve. Our study shows that preventing recurrence by monitoring and targeting dormant tumor cells is a strategy that holds real promise, and I hope it ignites more research in this area." Her statement underscores the immense psychological burden lifted by the prospect of a preventative measure.

Seizing the Window of Opportunity: The Biology of Dormancy

The foundation of this clinical success lies in years of meticulous preclinical research. Dr. Lewis Chodosh, MD, PhD, Chair of Cancer Biology and senior author of the study, had previously led extensive research aimed at unraveling the complex molecular pathways that allow dormant tumor cells to survive undetected in patients for decades. His work provided the critical insight that dormant cells operate under a vastly different biological program compared to actively growing cancer cells. This distinction is crucial because it means that drugs effective against proliferating tumors might be ineffective against dormant ones, and vice versa.

"Our research shows that this sleeper phase represents an opportunity to intervene and eradicate the dormant tumor cells before they have the chance to come back as aggressive, metastatic disease," Dr. Chodosh explained. "Surprisingly, we’ve found that certain drugs that don’t work against actively growing cancers can be very effective against these sleeper cells. This tells us that the biology of dormant tumor cells is very different from active cancer cells."

In the preclinical phase of the recently published research, Dr. Chodosh’s team conducted a series of sophisticated experiments in mouse models. They meticulously investigated the underlying mechanisms that enable tumor cell dormancy. This research identified two key cellular processes – autophagy and mTOR signaling – as critical pathways that dormant cells exploit to survive. Autophagy is a cellular recycling process, while mTOR signaling regulates cell growth and metabolism. By understanding these mechanisms, the researchers were able to identify existing, FDA-approved drugs that could specifically target and disrupt these pathways. Their experiments in mice demonstrated that two different drugs, already approved for other conditions, could effectively clear MRD, leading to significantly longer survival without cancer recurrence. This preclinical validation provided the strong rationale for moving these repurposed drugs into human clinical trials.

Translating Science into Clinical Reality: The CLEVER Trial Design

The journey from laboratory discovery to clinical application involved a two-pronged approach. First, Dr. DeMichele’s team initiated a crucial screening study. Breast cancer survivors who had completed their primary treatment within the last five years and had no evidence of active disease on standard scans were enrolled. The primary objective of this screening phase was to identify the presence of dormant tumor cells, specifically in the participant’s bone marrow, which is known to be a sanctuary site for MRD.

Only those patients confirmed to harbor dormant tumor cells were then eligible to enroll in the pivotal Phase II CLEVER clinical trial. In this randomized trial, participants received six cycles of treatment. Patients were assigned to either monotherapy (receiving one of the two study drugs) or combination therapy (receiving both drugs). The treatment regimens were well-tolerated, and the subsequent monitoring revealed that the drugs successfully cleared dormant tumor cells in the majority of patients within six to twelve months. The low recurrence rate observed during the median 42-month follow-up period stands in stark contrast to the expected recurrence rates for high-risk breast cancer survivors. This data strongly suggests that early intervention targeting dormant cells can significantly alter the natural history of the disease.

"We want to be able to give patients a better option than ‘wait and see’ after they complete breast cancer treatment," Dr. DeMichele stated, emphasizing the paradigm shift this research represents. "We’re encouraged by these results that we’re on the right track."

Broader Impact and Future Implications

The findings from the CLEVER trial carry profound implications across several domains:

1. Clinical Practice Transformation: This research paves the way for a new standard of care in breast cancer survivorship. Instead of simply monitoring patients and reacting to recurrence, clinicians could potentially identify high-risk individuals post-treatment and proactively intervene with preventative therapies. This could lead to a significant reduction in metastatic breast cancer diagnoses.

2. Personalized Medicine: The ability to detect MRD and then selectively treat those patients who harbor these cells represents a highly personalized approach to cancer care. It avoids unnecessary treatment for patients who are truly disease-free while providing crucial intervention for those most at risk.

3. Psychological Well-being: The "lingering fear" of recurrence is a constant companion for many breast cancer survivors. A preventative treatment strategy could alleviate much of this anxiety, significantly improving their quality of life post-treatment.

4. Economic Benefits of Repurposed Drugs: The use of existing, FDA-approved drugs for this new indication offers several advantages. Repurposed drugs typically have known safety profiles, are generally more affordable than newly developed oncology drugs, and can be brought to clinical use much faster, accelerating the translation of research into patient benefit.

5. Scientific Advancement: This study deepens our understanding of cancer biology, particularly the complex mechanisms of dormancy and resistance. It opens new avenues for research into other cancers that exhibit similar patterns of recurrence and provides a blueprint for targeting MRD in other malignancies.

6. Validation of Translational Research Funding: The success of this federally funded trial, supported by the National Cancer Institute (R01CA208273) and the Department of Defense (BC160784), along with contributions from philanthropic organizations like the V Foundation, Breast Cancer Research Foundation, QVC "Shoes on Sale," Avon Foundation, and Raynier Institute & Foundation, underscores the critical importance of investing in high-risk, high-reward translational research. These investments are vital for transforming basic scientific discoveries into tangible clinical solutions. Dr. DeMichele had previously presented interim outcomes data from this study at the European Society for Medical Oncology (ESMO) Congress 2023, generating early excitement within the oncology community.

Looking Ahead: Confirming and Expanding the Findings

Recognizing the immense potential of these initial findings, the Penn Medicine team is already advancing its research. They are actively enrolling patients in two larger, ongoing studies designed to confirm and extend the results observed in the CLEVER trial. These include the Phase II ABBY clinical trial and the Phase II PALAVY clinical trial, which are being conducted at multiple cancer centers across the United States. These larger trials are essential for validating the efficacy and safety of the preventative strategy in a broader patient population and for establishing its long-term benefits.

Patients interested in learning more about these or other breast cancer clinical trials at Penn Medicine are encouraged to contact [email protected]. The collective efforts of dedicated researchers, clinicians, and supportive funding bodies are bringing us closer than ever to a future where breast cancer recurrence is not just managed, but proactively prevented.